

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of September 2018**

Commission File Number: **001-32001**

**Aptose Biosciences Inc.**

(Translation of registrant's name into English)

251 Consumers Road, Suite 1105 Toronto, Ontario M2J 4R3 Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F [  ] Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

On September 25, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) [Exhibit 99.1](#). Press release dated September 25, 2018

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Aptose Biosciences Inc.**  
(Registrant)

Date: September 25, 2018

/s/ Gregory K. Chow  
Gregory K. Chow  
Senior Vice President and Chief Financial Officer

### Aptose to Present at Upcoming Investor Conferences in October 2018

SAN DIEGO, Calif. and TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the following upcoming conferences:

· **2018 Cantor Fitzgerald Global Healthcare Conference**

Date: Tuesday, October 2, 2018  
 Time: 8:00 a.m. EDT  
 Format: Company Presentation  
 Location: Intercontinental New York Barclay Hotel, New York City  
 Live webcast: Cantor Fitzgerald Conference Webcast Link

· **Leerink Partners Roundtable Series: Rare Disease & Oncology**

Date: Wednesday, October 3, 2018  
 Time: 2:00 p.m. EDT  
 Format: Fireside Chat  
 Location: Lotte New York Palace Hotel, New York City  
 Live webcast: Leerink Partners Conference Webcast Link

· **18<sup>th</sup> Annual Biotech in Europe Forum**

Date: Friday, October 5, 2018  
 Location: Centre Congress, Basel, Switzerland

- 9:45 a.m. CEST – Company Presentation
- 12:10 p.m. CEST – *Oncology II* – Advanced Therapeutics Panel

The live webcasts can also be accessed through the Aptose website at [www.aptose.com](http://www.aptose.com) and will be archived shortly after the live event and available for 90 days.

#### About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor expected to reach IND submission by the end of 2018 and is planned for development to treat AML and certain B cell malignancies. For further information, please visit [www.aptose.com](http://www.aptose.com).

For further information, please contact:

#### Aptose Biosciences

Greg Chow, CFO  
 647-479-9828  
[gchow@aptose.com](mailto:gchow@aptose.com)

#### SMP Communications

Susan Pietropaolo  
 201-923-2049  
[susan@smpcommunications.com](mailto:susan@smpcommunications.com)

#### LifeSci Advisors

Michael Wood  
 Managing Director  
 646-597-6983  
[mwood@lifesciadvisors.com](mailto:mwood@lifesciadvisors.com)